Obseva shows why red flags are worth heeding
A crucial second pivotal trial in uterine fibroids fails to dispel concerns about the company’s linzagolix.
Myovant socks it to Orilissa
Two years after Abbvie’s disappointing launch of Orilissa Myovant hails the development of something much better.
Upcoming events – Fibroid data for Obseva, as Inventiva turns to Nash
Phase III data for Obseva's uterine fibroid project linzagolix need to prove its safety, while Inventiva tests its pan-PPAR agonist lanifibranor in Nash.
Asco-GU: confirmation for Seattle and a reminder for Mirati
Incremental data revealed at the conference could give Mirati, Exelixis and Seattle Genetics renewed hope.
Avatera Medical becomes the newest robotic surgery group in Europe
The German start-up must navigate the hazards that have felled other surgical robot developers while simultaneously dealing with a more crowded market.
Reata’s worsened Cardinal results could still be good enough
The pivotal portion of bardoxolone’s Cardinal study can’t match earlier data, but is still sufficient for filing.
